Archives
-
Plastid DNA Breaks in Arabidopsis: DEtail-seq Insights
2026-08-19
This study introduces a genome-wide DEtail-seq map of plastid DNA breaks across Arabidopsis development, genetic backgrounds, and environmental conditions. It shows that plastid genome instability is shaped by tissue age, DNA repair and replication capacity, R-loop accumulation, and reactive oxygen species, providing a framework for investigating organellar genome maintenance.
-
Z-VAD-FMK in Apoptosis–Necroptosis Assays
2026-08-19
Z-VAD-FMK is more than a broad apoptosis blocker: it can help researchers determine whether caspase suppression unmasks alternative cell-death phenotypes during antiviral experiments. This guide connects its biochemical use to poxvirus necroptosis research and practical assay interpretation.
-
IR-1061: Smarter NIR-II Imaging Assay Design
2026-08-18
IR-1061 is a near infrared fluorescent dye for OTN-NIR and deep-tissue research. This guide explains how solvent handling, carrier charge, dye loading, and aggregation determine assay performance beyond simple fluorophore selection.
-
HyperFluor™ 594 Goat Anti-Rabbit IgG Guide
2026-08-18
The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody is a goat anti-rabbit IgG secondary antibody for fluorescence-based detection. Its 590 nm excitation maximum and 617 nm emission maximum support immunocytochemistry, immunohistochemistry, flow cytometry, and compatible ELISA workflows.
-
EdU Imaging Kits (HF594) in Resistance Biology
2026-08-17
EdU Imaging Kits (HF594) connect S-phase DNA synthesis measurement with mechanistic studies of drug-resistant cancer. This article explains how the K2243 workflow can sharpen proliferation, pharmacodynamic, and combination-treatment decisions without overinterpreting EdU as a complete measure of tumor response.
-
Doxorubicin A3966: Reliable Cytotoxicity Workflows
2026-08-17
This scenario-driven guide explains how Doxorubicin (SKU A3966) can standardize cytotoxicity, viability, and persister-cell experiments. It connects mechanism, dosing, formulation, storage, data interpretation, and vendor selection to practical laboratory decisions supported by product information and recent ferroptosis research.
-
Spatially Concentrated ABE Correction of PLP1 Mutations
2026-08-16
This Nucleic Acids Research study introduces spatially concentrated adenine base editors that improve PLP1 A243V correction in oligodendrocytes without relying on greater intrinsic TadA* catalytic activity. The compact cABE-2.0 architecture combines local editor recruitment, AAV-compatible Cas9 engineering, and reduced transcriptome-wide RNA off-target activity, providing a mechanistic framework for developing treatments for Pelizaeus–Merzbacher disease and related myelin disorders.
-
CAIPS: AI Prognostic Stratification in HCC
2026-08-15
The reference study developed a seven-gene consensus artificial intelligence-derived prognostic signature (CAIPS) by benchmarking machine-learning strategies across six multi-center hepatocellular carcinoma cohorts. Its integration of prognostic modeling, multi-omics interpretation, drug repositioning, and PITX1 functional validation provides a framework for risk stratification and treatment-response hypothesis generation, although prospective clinical validation remains necessary.
-
HyperFluor 488 Goat Anti-Mouse IgG in Vascular Imaging
2026-08-14
Learn how the HyperFluor 488 Goat Anti-Mouse IgG fluorescently labeled secondary antibody can support multi-readout studies of radiation-induced endothelial injury. This assay-focused guide connects immunofluorescence, flow cytometry, and western blot design to findings from a resveratrol vascular-injury model.
-
A Vascularized 3D Model of Neuron–Microglia Crosstalk
2026-08-14
Han and colleagues developed a geometrically engineered silk fibroin scaffold that integrates human-induced neural stem cells, vascular organoids, and microglia in a three-dimensional immune-neurovascular model. The study shows that microglial effects depend strongly on phenotype and identifies SDF-1/CXCR4 signaling as a mechanism by which M2 microglia and vascular organoids support neuronal and vascular maturation.
-
From Variant Immunity to Translational Readouts
2026-08-13
Variant-aware vaccine development depends on more than antigen design. This thought-leadership article connects the preclinical RQ3025 findings with a practical strategy for detecting human IgG across immunofluorescence, Western blotting, flow cytometry, and ELISA using HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody.
-
2,7-Dichlorodihydrofluorescein diacetate ROS Workflows
2026-08-13
Build more interpretable intracellular ROS experiments with DCFH-DA across microscopy, flow cytometry, and plate readers. This guide connects practical assay design with granulosa-cell oxidative-stress research while emphasizing controls, normalization, and probe-specific limitations.
-
Fluorinated-Sorbitol Polyplexes for mRNA Vaccines
2026-08-12
The reference study develops fluorinated polyethyleneimine with sorbitol functionalization (PFS), a polymeric mRNA carrier designed to improve both cellular uptake and endosomal escape while limiting toxicity. Reporter and SARS-CoV-2 spike mRNA experiments in macrophage-like cells and mice showed effective protein expression and vaccine-induced neutralization, positioning PFS as a promising alternative to lipid nanoparticle delivery that still requires broader validation.
-
ML365 for Reliable Cell and Ion Channel Assays
2026-08-12
This scenario-driven guide explains how ML365 (SKU B8483) can improve experimental consistency when TASK1 modulation intersects with viability, proliferation, cytotoxicity, or inflammatory readouts. It combines product specifications with literature evidence, assay-compatibility guidance, protocol parameters, and practical vendor-selection criteria for biomedical laboratories.
-
Novel PDK4 Inhibitors for Metabolic Disease
2026-08-11
This study used anthraquinone hit optimization to discover a new series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, identifying compound 8c as a promising lead. Its biochemical activity, metabolic properties, animal efficacy, and anticancer effects support PDK4 as a pharmacological target while also highlighting the need for further selectivity, safety, and translational studies.